Larvol Veri

BIOMARKER:

EGFR T790M

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	almonertinib Sensitive: A1 - Approval almonertinib Sensitive : A1
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	rociletinib Sensitive: C2 – Inclusion Criteria rociletinib Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	ASK120067 Sensitive: C2 – Inclusion Criteria ASK120067 Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	olmutinib Sensitive: C2 – Inclusion Criteria olmutinib Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	AST2818 Sensitive: C2 – Inclusion Criteria AST2818 Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	AC0010MA Sensitive: C2 – Inclusion Criteria AC0010MA Sensitive : C2
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	D-0316 Sensitive: C2 – Inclusion Criteria D-0316 Sensitive : C2
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C3 – Early Trials bevacizumab + osimertinib Resistant : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES